Structure-guided engineering of CCL27 enhances natural ligand CAR T-cells against CCR10 for multiple myeloma
Chilakapati, N.; Patino-Escobar, B.; Chen, E. Y.; Dalal, R.; de Montagnac, J.; Johnson, H.; Kang, A. S.; Akagi, N.; Ramos, E.; Phojanakong, P.; Salangsang, F.; Zeng, Y.; Chari, A.; Chung, A.; Kumar, A. D.; Martin, T. G.; Shy, B. R.; Steri, V.; Karlon, W. J.; Kortemme, T.; Barwick, B. G.; Wiita, A. P.
Show abstract
Despite the success of BCMA CAR-Ts, many multiple myeloma patients relapse and require additional therapeutic options. Our group previously identified the chemokine receptor CCR10 as a potential alternate target to address this need. Here, we validated CCR10 expression on primary myeloma tumors and sought to develop CAR T-cells against CCR10, utilizing its natural ligand CCL27 as a CAR binding element. However, CARs based on the native CCL27 sequence were ineffective. We thus utilized computational modeling and structure-guided engineering to inform rational mutations along the CCL27-CCR10 interface, exploiting a hydrophobic pocket on CCR10. This effort identified CCL27 mutants with an additional N-terminal aromatic amino acid that dramatically improved the efficacy of CCL27-based CAR-Ts to near that of current anti-BCMA CAR-Ts. We validated key amino acid contacts at the CCL27-CCR10 interface, which contribute to increased CAR binding avidity, predicted to be influenced by increased Van der Waals interactions. Lastly, we found that the CCL27 mutants have no toxicity in the hematopoietic compartment. This work illustrates the potential of engineering natural ligand CAR-Ts beyond their wild-type sequences and underscores the translational potential of engineered CCL27 mutant CAR-Ts.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma 95%
- Cell lineage as a predictor of immune response in neuroblastoma 94%
- Negative trade-off between neoantigen repertoire breadth and the specificity of HLA-I molecules shapes antitumour immunity 94%
Similar papers in this journal
- Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies 97%
- Pooled screening for CAR function identifies novel IL13Rα2-targeted CARs for treatment of glioblastoma 96%
- Distinct sets of molecular characteristics define tumor-rejecting neoantigens 95%
Similar papers in this journal
- Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells 96%
- Systems medicine dissection of chromosome 1q amplification reveals oncogenic regulatory circuits and informs targeted therapy in cancer 95%
- A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia 94%
Similar papers in this journal
- Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy 95%
- NRCAM variant defined by microexon skipping is a targetable cell surface proteoform in high-grade gliomas 95%
- Cancer-cell-derived cGAMP limits the activity of tumor-associated CD8+ T cells 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.